What can Merck afford to buy now? ‘ANYTHING’ it wants

Bioregnum Opinion Column by John Carroll

With Keytruda bulling its way past the $5 billion mark for Q2 sales, you could say that the top execs at Merck can be believed when they say how keenly interested they are in using its cash reserves...

Click to view original post